{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:44:40Z","timestamp":1791225880719,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aiche.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Bioengineering &amp;amp; Transla Med"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Choline geranate deep eutectic solvent\/ionic liquid (CAGE) has shown several desirable therapeutic properties including antimicrobial activity and ability to deliver drugs transdermally in research laboratories. Here, we describe the first report of clinical translation of CAGE from the lab into the clinic for the treatment of rosacea, a common chronic inflammatory skin disorder that affects the face. We describe the seven steps of clinical translation including (a) scale\u2010up, (b) characterization, (c) stability analysis, (d) mechanism of action, (e) dose determination, (f) GLP toxicity study, and (g) human clinical study. We describe the challenges and outcomes in these steps, especially those that uniquely arise from the deep eutectic nature of CAGE. Our translational efforts led to a 12\u2010week open\u2010label phase 1b cosmetic study with CAGE\n                    <jats:sub>1:2<\/jats:sub>\n                    gel (CGB400) in mild\u2013moderate facial rosacea in 26 patients where CGB400 exhibited a marked reduction in the number of inflammatory lesions. These results demonstrate the therapeutic potential of CGB400 for treating rosacea as well as it provides insights into the translational journey of deep eutectic solvents, in particular CAGE, for dermatological applications.\n                  <\/jats:p>","DOI":"10.1002\/btm2.10191","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T12:41:46Z","timestamp":1602852106000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Clinical translation of choline and geranic acid deep eutectic solvent"],"prefix":"10.1002","volume":"6","author":[{"given":"Justin","family":"Ko","sequence":"first","affiliation":[{"name":"Department of Dermatology Stanford University School of Medicine  Redwood City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhirup","family":"Mandal","sequence":"additional","affiliation":[{"name":"CAGE Bio, Inc.  San Carlos California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Dhawan","sequence":"additional","affiliation":[{"name":"Center for Dermatology Clinical Research, Inc.  Fremont California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Shevachman","sequence":"additional","affiliation":[{"name":"CAGE Bio, Inc.  San Carlos California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-8305","authenticated-orcid":false,"given":"Samir","family":"Mitragotri","sequence":"additional","affiliation":[{"name":"John A. Paulson School of Engineering and Applied Sciences Harvard University  Cambridge Massachusetts USA"},{"name":"Wyss Institute of Biologically Inspired Engineering at Harvard University  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1218-0438","authenticated-orcid":false,"given":"Nitin","family":"Joshi","sequence":"additional","affiliation":[{"name":"CAGE Bio, Inc.  San Carlos California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1361574"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16481"},{"issue":"6","key":"e_1_2_8_4_1","first-page":"348","article-title":"Burden of disease: the psychosocial impact of rosacea on a patient's quality of life","volume":"6","author":"Huynh TT","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17590"},{"issue":"6","key":"e_1_2_8_6_1","first-page":"663","article-title":"The pathophysiology of rosacea","volume":"144","author":"Mc Aleer MA","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.16537.1"},{"issue":"1","key":"e_1_2_8_8_1","first-page":"41","article-title":"MIRVASO (brimonidine tartrate) topical gel 0.33%","volume":"12","author":"Abramovits W","year":"2014","journal-title":"Skinmed"},{"issue":"12","key":"e_1_2_8_9_1","first-page":"808","article-title":"Oxymetazoline hydrochloride 1% cream (Rhofade) for persistent facial erythema associated with rosacea","volume":"97","author":"Garcia C","year":"2018","journal-title":"Am Fam Physician"},{"issue":"3","key":"e_1_2_8_10_1","first-page":"222","article-title":"1% Ivermectin cream (Soolantra) for the treatment of rosacea","volume":"13","author":"Scheinfeld N","year":"2015","journal-title":"Skinmed"},{"issue":"6","key":"e_1_2_8_11_1","first-page":"641","article-title":"The efficacy and safety of azelaic acid 15% foam in the treatment of facial acne vulgaris","volume":"17","author":"Hashim PW","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2005.04866.x"},{"issue":"22","key":"e_1_2_8_13_1","first-page":"2327","article-title":"New insights in the pathogenesis and treatment of rosacea","volume":"128","author":"Palatsi R","year":"2012","journal-title":"Duodecim"},{"issue":"6","key":"e_1_2_8_14_1","first-page":"17","article-title":"The burden of illness of erythematotelangiectatic rosacea and papulopustular rosacea: findings from a web\u2010based survey","volume":"10","author":"Del Rosso JQ","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00322-5"},{"issue":"6","key":"e_1_2_8_16_1","first-page":"17","article-title":"Update on the management of rosacea from the American Acne and Rosacea Society (AARS)","volume":"12","author":"Del Rosso JQ","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S194074"},{"issue":"3","key":"e_1_2_8_18_1","first-page":"113","article-title":"Rate of adverse events and healthcare costs associated with the topical treatment of rosacea","volume":"10","author":"Williamson T","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201600086"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1403995111"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.12.036"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201601411"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1914426116"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.048090-0"},{"issue":"1","key":"e_1_2_8_25_1","first-page":"20","article-title":"Kallikrein 5\u2010mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit","volume":"7","author":"Two AM","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222211"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315622585"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581812462039"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.02.005"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jat.3004"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12538909"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901103"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10083"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1722338115"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.08.006"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1616"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.351"},{"issue":"1","key":"e_1_2_8_38_1","first-page":"26","article-title":"Rosacea, reactive oxygen species, and azelaic acid","volume":"2","author":"Jones DA","year":"2009","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["Bioengineering &amp; Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/btm2.10191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/btm2.10191","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aiche.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/btm2.10191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:12Z","timestamp":1760035572000},"score":1,"resource":{"primary":{"URL":"https:\/\/aiche.onlinelibrary.wiley.com\/doi\/10.1002\/btm2.10191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/btm2.10191"],"URL":"https:\/\/doi.org\/10.1002\/btm2.10191","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BTM2.10191\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTM2.10191\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTM2.10191\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTM2.10191\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTM2.10191\/v2\/decision1","asserted-by":"object"}]},"ISSN":["2380-6761","2380-6761"],"issn-type":[{"value":"2380-6761","type":"print"},{"value":"2380-6761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"2020-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e10191"}}